In:
Artificial Organs, Wiley, Vol. 47, No. 8 ( 2023-08), p. 1404-1412
Abstract:
Little is known about safety and efficacy of the use of Impella 5.5 compared to previous iterations in the setting of Impella with Veno‐Arterial Extracorporeal Membrane Oxygenation Support as ECPELLA. Methods Consecutive patients who were treated by ECPELLA with surgically implanted axillary Impella 5.5 ( N = 13) were compared with patients supported by ECPELLA with percutaneous femoral Impella CP or 2.5 (Control, N = 13). Results The total ECPELLA flow was higher in ECPELLA 5.5 group (6.9 vs. 5.4 L/min, p = 0.019). Actual hospital survival was higher than predicted and comparable in both groups (ECPELLA 5.5, 61.5% vs. Control, 53.8%, p = 0.691). Both total device complications (ECPELLA 5.5, 7.7% vs. Control, 46.1%, p = 0.021) and Impella‐specific complications (ECPELLA 5.5, 0% vs. Control, 30.8%, p = 0.012) were significantly lower in the ECPELLA 5.5 group. Conclusions Utilization of Impella 5.5 in the setting of ECPELLA provides greater hemodynamic support with a lower risk of complications compared to Impella CP or 2.5.
Type of Medium:
Online Resource
ISSN:
0160-564X
,
1525-1594
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2003825-2